Author: Troy Fugate
-
North Carolina’s Biopharma Boom: Opportunities, Risks & Leadership Imperatives
In recent years, North Carolina has emerged as one of the most dynamic hubs of biopharmaceutical innovation and manufacturing in the U.S. With strong academic institutions, a growing workforce, favorable […]
-
What a Night of Connection and Collaboration — BPD Roundtable Dinner Recap
The Oct 16, 2025 BPD Roundtable Dinner was nothing short of fantastic. From the first handshake during the networking hour to the last shared insight at the tables, the energy […]
-
GeminiBio Releases Whitepaper on Human AB Serum
GeminiBio has released an essential white paper on human serum use in cell therapy development and manufacturing. This guide delivers expert insight on regulatory, supply chain, and supplier considerations — […]
-
Apheresis Guide – Your Chance for Input
After approximately four years of working on the guide, I’m happy to announce that our efforts and dedication have paid off. The PDA has published the draft of BSR/PDA Standard […]
-
Top 5 FDA Observations for Cell & Gene Therapy Firms in 2025
Cell and gene therapies promise transformative outcomes but they also carry elevated risk and regulatory scrutiny. As the CGT sector matures, the FDA has sharpened its focus on manufacturing, control […]